Study S001412

Effects of Victoza® (Liraglutide) Versus Lyxumia® (Lixisenatide) on Gastroesophageal Reflux, Gastric Emptying and Gastric Acid Secretion

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT02231658
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: SINGLE
Status: TERMINATED
Enrollment: 109
Start: 2015-07-16
Primary completion: 2018-07-23
Lead sponsor: Profil Institut für Stoffwechselforschung GmbH
Conditions: Diabetes Mellitus
Interventions: DRUG:Liraglutide; DRUG:Lixisenatide
Results posted: FALSE

Registered primary outcomes

Change from baseline (week -1) in the number of reflux episodes [24 hours after 10 weeks of treatment]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0007679	Effects of Lixisenatide Versus Liraglutide (Short- and Long-Acting GLP-1 Receptor Agonists) on Esophageal and Gastric Function in Patients With Type 2 Diabetes. Quast DR, Diabetes care	2020	Randomized trial	PMID 32647054 DOI	cites ClinicalTrials.gov:NCT02231658; registry reference DERIVED:32647054